Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Jul 2018 Status changed from not yet recruiting to recruiting.
- 01 May 2018 Planned initiation date changed from 15 Apr 2018 to 15 Jun 2018.